BioWorld / Grant
Biopharma grants in 2025
| ||||||
| Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
| CEPI to award funding to develop Afrigen's mRNA vaccine against Rift Valley fever | Afrigen Biologics Pty Ltd. | Coalition for Epidemic Preparedness Innovations | $6.20 | 1/20/2025 |
| DARPA to award Arzeda funding for its AI platform for rapid and strong design of proteins | Arzeda Corp. | Defense Advanced Research Projects Agency | Payment unspecified | 1/23/2025 |
| Scaleready awarded funding to Brainchild to support the development and commercial of BCB-276 against diffuse intrinsic pontine glioma | Brainchild Bio Inc. | Scaleready LLC | $0.30 | 1/21/2025 |
| NIH to award Cambium Oncology funding to support the clinical development of ANT-308 for acute myeloid leukemia | Cambium Oncology LLC | National Institutes of Health | $2.40 | 1/13/2025 |
| OEP to invest in Cambium Oncology to advance the clinical development of ANT-308 for acute myeloid leukemia | Cambium Oncology LLC | Orient Europharma Co. Ltd. | $5.00 | 1/13/2025 |
| CARB-X to award Clarametyx funding to advance the development of CMTX-301 into lead optimization, to prepare for preclinical (IND-enabling) and phase 1 evaluation against bacterial infections | Clarametyx Biosciences Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $2.60 | 1/7/2025 |
| KIAT to award funding to develop Evotec's tRNA synthetases against lung diseases | Evotec SE | Korea Institute for Advancement of Technology | $4.50 | 1/22/2025 |
| LifeArc to award Glox funding to develop precision antibiotics against cystic fibrosis | Glox Therapeutics Ltd. | Lifearc Pvt. Ltd. | $0.64 | 1/21/2025 |
| Michael J. Fox Foundation to award Grifols' funding to identify plasma-based biomarkers and to develop diagnostic tools and new disease-modifying therapeutics for Parkinson's disease | Grifols SA | The Michael J Fox Foundation for Parkinson's Research | $21.00 | 1/14/2025 |
| CARB-X to award Immunartes funding to develop a monoclonal antibody against Staphylococcus aureus infections | Immunartes LLC | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $0.73 | 1/23/2025 |
| NIA to award Jupiter Neurosciences funding to evaluate Jotrol against Alzheimer’s disease | Jupiter Neurosciences Inc. | National Institute on Aging | Payment unspecified | 1/13/2025 |
| NIH to award KI funding for the research project against autism | Karolinska Institutet | National Institutes of Health | $2.50 | 1/21/2025 |
| ERC to award KI funding to develop vaccines adapted to genetic variations against multiple indications | Karolinska Institutet | European Research Council | $0.16 | 1/23/2025 |
| Promobilia foundation to award Karolinska Institutet funding to support development of a treatment for inherited retinal diseases | Karolinska Institutet | Promobilia Foundation | $0.93 | 1/31/2025 |
| Bill & Melinda Gates Foundation to award Micron Biomedical funding to develop measles-rubella vaccine | Micron Biomedical Inc. | Bill & Melinda Gates Foundation | $7.50 | 1/7/2025 |
| CEPI to award funding to study Micron’s microarray technology to deliver vaccine against COVID-19 | Micron Biomedical Inc. | Coalition for Epidemic Preparedness Innovations | $3.70 | 1/8/2025 |
| BARDA to award Micron Biomedical funding to develop mRNA-based broad protecting flu vaccine | Micron Biomedical Inc. | Biomedical Advanced Research and Development Authority | $2.00 | 1/13/2025 |
| BARDA to award Moderna funding to develop mRNA-based avian-variant vaccines | Moderna Inc. | Biomedical Advanced Research and Development Authority | $590.00 | 1/17/2025 |
| NIH to award Ocean Biomedical funding to identify vaccine targets against malaria | Ocean Biomedical Inc. | National Institutes of Health | Payment unspecified | 1/29/2025 |
| BARDA to award Partner Therapeutics funding for a phase II study of Leukine in sepsis patients | Partner Therapeutics Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 1/9/2025 |
| CARB-X to award Peptilogics funding to develop zaloganan-CR to prevent fracture related infections | Peptilogics Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $3.30 | 1/9/2025 |
| Osteosarcoma Institute to award Peptomyc funding for the phase II clinical study of OMO-103 in patients with advanced osteosarcoma | Peptomyc SL | The Osteosarcoma Institute | Payment unspecified | 1/16/2025 |
| Bill & Melinda Gates Foundation to award Recibiopharm funding to advance RNA manufacturing | Recipharm AB | Bill & Melinda Gates Foundation Trust | Payment unspecified | 1/13/2025 |
| CARB-X to award Rhode Island Hospital funding to study proof-of-concept of PCR approach feasibility of direct from blood detection of bacterial pneumonia | Rhode Island Hospital | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $1.00 | 1/28/2025 |
| Scaleready to award Seattle Children's Research Institute funding for CAR-T platform development | Seattle Children’s Research Institute | Scaleready LLC | $0.12 | 1/8/2025 |
| CIRM to award Senti Biosciences funding to develop SENTI-202 program | Senti Biosciences Inc. | California Institute for Regenerative Medicines | $1.50 | 1/1/2025 |
| BARDA to award funding to develop Shionogi's S-892216 against COVID-19 infection | Shionogi and Co. Ltd. | Biomedical Advanced Research and Development Authority | $375.00 | 1/16/2025 |
| CIRM to award UCLA funding to develop a hematopoietic stem cell gene therapy (HSC-GT) against Angelman syndrome | University of California Los Angeles | Foundation for Angelman Syndrome Therapeutics UK | $5.80 | 1/30/2025 |
| CARB-X to award JLU a grant to support the development of ADC-56 targeting Gram-negative pathogens | University of Giessen | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $0.61 | 1/16/2025 |
| NIH to award Vast Therapeutics funding to develop ALX-1 for cystic fibrosis and other chronic lung infections | Vast Therapeutics Inc. | National Institutes of Health | $2.00 | 1/21/2025 |
| Scaleready to award Vaxcell-Bio a G-Rex Grant to support the development of VYPC-1 and Vax-CAR-MIL therapy against cancer | Vaxcell-Bio Co. Ltd. | Scaleready LLC | $0.21 | 1/8/2025 |
| BARDA to award Vaxxas funding to advance commercialization of microneedle patch-based mRNA vaccines | Vaxxas Pty. Ltd. | Biomedical Advanced Research and Development Authority | $2.00 | 1/15/2025 |
| CEPI to award Vaxxas funding to develop heat-stable, dried-formulation mRNA vaccines, including GBP-56 delivered using needle-free high-density microarray patch | Vaxxas Pty. Ltd. | Coalition for Epidemic Preparedness Innovations | $4.80 | 1/22/2025 |
| IFLI to award an investment to Verismo to advance the development of SynKIR-310 pipeline for follicular lymphoma and other non-Hodgkin lymphoma subtypes | Verismo Therapeutics Inc. | Institute for Follicular Lymphoma Innovation | $4.05 | 1/7/2025 |
| Innosuisse to award Ymmunobio funding to develop Radio-pharmaceutical YB-800 for solid tumors | Ymmunobio AG | Innosuisse Management AG | Payment unspecified | 1/23/2025 |
| European Innovation Council to award Alzecure funding to conduct a phase II clinical study of ACD-856 for Alzheimer's disease and pain | Alzecure Pharma AB | European Commission | $2.67 | 2/17/2025 |
| Department of Defense to award Cedars-Sinai funding to advance the development of ENV-205 against chemotherapy drug resistance and cachexia | Cedars-Sinai Medical Center | US Department of Defense | $0.60 | 2/18/2025 |
| DeGregorio Family Foundation to award Columbia University funding to support the development of TFF2-MSA for gastroesophageal cancer treatment | Columbia University Irving Medical Center | DeGregorio Family Foundation | $0.12 | 2/6/2025 |
| March of Dimes to award Columbia University Irving Medical Center funding to immune-related proteins for spontaneous preterm birth | Columbia University Irving Medical Center | March of Dimes (US) | $0.20 | 2/18/2025 |
| CIRM to award funding to develop CRD's antisense oligonucleotide therapy against SCA3 | Cure Rare Disease Inc. | California Institute of Regenerative Medicine | $5.69 | 2/6/2025 |
| NIAID to award Dare? Bioscience funding to support non-clinical activities to support the development of DARE-HPV | Dare Bioscience Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 2/6/2025 |
| CIRM to award funding to develop Entos' ENTLEP-001 against congenital generalized lipodystrophy | Entos Pharmaceuticals Inc. | California Institute of Regenerative Medicine | $4.00 | 2/5/2025 |
| CEPI to award Ethris funding to support proof-of-concept research to develop spray-dried RNA vaccines | Ethris GmbH | Coalition for Epidemic Preparedness Innovations | $5.00 | 2/11/2025 |
| Innosuisse to award Haya Therapeutics funding to develop lncRNA against solid tumors | Haya Therapeutics SA | Innosuisse Management AG | $1.71 | 2/12/2025 |
| LCRF and ICRF to award Hebrew University of Jerusalem funding to support IGF2BP1 against Colorectal Carcinomas | Hebrew University of Jerusalem | Lung Cancer Research Foundation | $0.18 | 2/18/2025 |
| Pace to award Infex funding to develop BamA inhibitor for MDR resistant gram negative bacterial infections | Infex Therapeutics Ltd. | Pathways to Antimicrobial Clinical Ef?cacy | $1.28 | 2/17/2025 |
| Erling-Persson Foundation to award KI funding to develop therapy against Parkinson’s disease | Karolinska Institutet | Familjen Erling-Perssons Stiftelse | $0.74 | 2/19/2025 |
| MJFF to award Kazia Therapeutics funding to evaluate paxalisib for the treatment of Parkinson's disease | Kazia Therapeutics Ltd. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 2/20/2025 |
| NIAID to award Lactiga funding to advance LCTG-001 against immune deficiency | Lactiga Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 2/3/2025 |
| CIRM to award Navega funding to support the preclinical development of NT-Z001 for chronic neuropathic pain | Navega Therapeutics Inc. | California Institute of Regenerative Medicine | $4.00 | 2/4/2025 |
| Ramsay Hospital Research Foundation to award Redhill Biopharma funding for phase II study of opaganib in combination with darolutamide for metastatic castrate-resistant prostate cancer | Redhill Biopharma Ltd. | Ramsay Health Care Ltd. | Payment unspecified | 2/4/2025 |
| Medical Research Agency to award Ryvu Therapeutics a funding to develop active substances for antibody drug conjugates | Ryvu Therapeutics SA | Agencja Bada? Medycznych | $2.48 | 2/17/2025 |
| Eurostars to award Teitur funding to develop peptide therapeutics for hearing loss | Teitur Trophics ApS | Eurostars | $2.13 | 2/5/2025 |
| CPRIT to award University of Texas MD Anderson funding for cancer research | The University of Texas MD Anderson Cancer Center | Cancer Prevention and Research Institute of Texas | $23.00 | 2/19/2025 |
| NIH to award TGen funding to conduct a preclinical study of SIWA-318 to target and eliminate senescent cells in PDAC | Translational Genomics Research Institute | National Institutes of Health | $0.49 | 2/11/2025 |
| Wellcome to award University of Bath funding to study cognitive decline and premature brain ageing in psychotic disorders, including schizophrenia | University of Bath | Wellcome Ltd. | $4.48 | 2/17/2025 |